Drug Profile
Ancremonam - Boston Pharmaceuticals
Alternative Names: BOS-228; LYS-228Latest Information Update: 09 Dec 2022
Price :
$50
*
At a glance
- Originator Novartis
- Class Amides; Amines; Antibacterials; Azetidines; Carboxylic acids; Cyclopropanes; Monobactams; Organic sulfur compounds; Oxazolidinones; Small molecules; Thiazoles
- Mechanism of Action Penicillin-binding protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Bacterial infections
Most Recent Events
- 09 Dec 2022 Phase-II development is ongoing in USA, Denmark and Greece (Boston Pharmaceuticals pipeline, December 2022)
- 19 Feb 2021 Chemical structure information added
- 26 Oct 2018 Novartis terminates a phase II trial in Bacterial infections in the US, Denmark and Greece (NCT03377426)